Product Description
Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist with very good oral activity, central nervous system penetration and a long (180-hour) plasma half-life. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28393710/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Belgium | European Medicines Agency | France | Germany | Hungary | Ireland | Italy | Lithuania | Poland | Portugal | Spain | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other
Phase 2: Other|Sarcoma|Chronic Cough|Glioma|Oncology Unspecified|Anesthesia Related
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02382666 |
PR-11-5022-C | P1 |
Completed |
Healthy Volunteers |
2015-08-01 |
2019-03-20 |
Treatments |
|
NCT02434861 |
PR-11-5021-C | P1 |
Completed |
Healthy Volunteers |
2015-07-01 |
2019-03-20 |
Treatments |
|
NCT02285647 |
PR-11-5016-C | P1 |
Completed |
Healthy Volunteers |
2015-04-01 |
2019-03-20 |
Treatments |
|
NCT02991456 |
Pro00076418 | P2 |
Completed |
Glioma |
2022-05-09 |
2024-10-16 |
||
NCT03960151 |
HCRN GU16-254 | P2 |
Withdrawn |
Oncology Unspecified |
2021-05-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT02732015 |
NCI-2016-00801 | P2 |
Terminated |
Sarcoma |
2020-07-10 |
2024-11-27 |
Primary Endpoints |
|
NCT00539721 |
P04937 | P2 |
Completed |
Anesthesia Related |
2008-07-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
2005-004712-73 |
2005-004712-73 | P2 |
Completed |
Other |
2008-03-27 |
2022-03-12 |
Treatments |
|
NCT00394966 |
P04351 | P2 |
Completed |
Other |
2008-03-01 |
2019-03-21 |
Treatments |
|
NCT00506545 |
Study P04888 | P2 |
Completed |
Chronic Cough |
2007-10-01 |
2022-05-04 |
Primary Endpoints |
|
NCT01499849 |
TS-P04832 | P3 |
Completed |
Other |
2014-05-01 |
2024-10-16 |
||
2010-022742-25 |
2010-022742-25 | P3 |
Completed |
Other |
2014-04-10 |
2022-03-13 |
Treatments |
|
NCT01500213 |
HEC | P3 |
Completed |
Other |
2014-03-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
2010-022743-37 |
2010-022743-37 | P3 |
Completed |
Other |
2014-02-24 |
2022-03-13 |
Treatments |
|
2010-022746-24 |
2010-022746-24 | P3 |
Completed |
Other |
2014-02-19 |
2022-03-13 |
Treatments |
|
NCT01500226 |
TS-P04834 | P3 |
Completed |
Other |
2014-02-01 |
2024-10-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/26/2023 |
News Article |
Chemotherapy-Induced Nausea and Vomiting Drugs Market, Global Outlook and Forecast 2023-2032 |
|
03/09/2023 |
News Article |
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development |
|
03/06/2023 |
News Article |
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors |
|
10/01/2021 |
News Article |
Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development |